Objective To evaluate the response rate and adverse reaction of metastatic and recurrent breast cancer patients treated with xeloda.

Methods: Xeloda 2 500 mg/ m 2/ day in dividing two dose per oral continued for two weeks, then stopped for one to two weeks.

方法：希罗达2500mg/m2·d-1，分2次口服，连续口服2周，停药1～2周；

It was began the registration of clinical trials in Beijing, Shanghai, Guangzhou and other places of the five national anticancer drug ′ s clinical trial research centers in November 1999. Then it was listed in China as the trade name "Xeloda".

于1999年11月开始由北京、上海、广州等地的5个国家抗肿瘤药物临床试验研究中心进行注册临床试验，并以商品名希罗达在中国上市。

The Clinical Observation of Xeloda Combined with Taxotere in the Treatment of Advanced Gastric Cancer

希罗达联合泰素帝治疗晚期胃癌的疗效观察

Clinical Observation to Postoperative Recurrence of Rectal Cancer Treated with Three Dimensional-conformal Radiotherapy Combined with Xeloda

三维适形放疗同步希罗达化疗治疗直肠癌术后复发的临床观察

Progress of Study on Prevention and Treatment of Xeloda Induced Hand-foot Syndrome by Measures of Chinese and Western Medicine

希罗达等致手足综合征中、西医防治措施研究进展

Conclusion Xeloda is suitable for the chemotherapy of malignant solid tumor of digestive tract.

结论希罗达可能适宜用于消化道恶性实体肿瘤化疗。

In the xeloda group, diarrhea in 28%, stomatitis in 16. 6% and hand-foot syndrome in 38. 9%.

希罗达组副反应主要为腹泻（28%）、手足综合征（38.9%）和口炎（16.6%）。

AIM: To investigate the effect of capecitabine ( xeloda) by preoperation administration on the microvessel density ( MVD) and expression of thymidine phosphorylase/ platelet-derived endothelial cell growth factor ( TP/ PD-ECGF) in patients with colorectal cancer.

目的：探讨术前希罗达化疗对结直肠癌胸苷磷酸化酶/血小板衍化内皮细胞生长因子（TP/PD-ECGF）表达、肿瘤组织微血管密度（MVD）的影响。

Clinical Studies of oxaliplatin and capecitabine ( Xeloda) in the treatment of elderly patients with Advanced Gastric carcinoma

奥沙利铂联合卡培他滨治疗老年晚期胃癌的临床研究

Docetaxel and Xeloda Combined Chemotherapy in Anthracyclines Resistant Advanced Breast Cancer

多西他赛联合希罗达治疗蒽环类耐药性晚期乳腺癌

CONCLUSION: Preoperation chemotherapy of xeloda can decrease the activity of TP/ PD-ECGF and inhibit the angiogenesis in colorectal cancer.

结论：希罗达术前化疗能使TP/PD-ECGF活性降低，抑制结直肠癌肿瘤血管生成。

Clinical observation of 36 cases with metastatic breast cancer treated by xeloda combining with with docetaxel

希罗达联合多西他赛治疗转移性乳腺癌36例临床观察

Objective: to observe the clinical effect of TCM Drug Huwei Yufu Decoction in treating xeloda related hand-foot syndrome.

目的：观察中药护胃愈肤汤治疗希罗达相关性手足综合症临床疗效。

The Clinical Study of Celecoxib Combined with Xeloda Metronomic Chemotherapy in the Treatment of the Elderly with Advanced Gastric Cancer

塞来昔布/希罗达节拍化疗治疗老年晚期胃癌的临床研究

The Observation of Safety and Efficacy of Continuous-Infusion 5-Fluorouracil Versus Xeloda for Gastrointestinal Cancer

5-Fu静脉泵持续输注与口服希罗达治疗消化道肿瘤的安全性及疗效的观察

Clinical Observation of 33 Patients with Advanced Breast Cancer Treated with Docetaxel and Xeloda

多西紫杉醇联合希罗达治疗晚期乳腺癌33例临床观察

METHODS: Immunohistochemical staining of CD34 and TP/ PD-ECGF monoclonal antibodies was performed in 32 colorectal cancer patients with preoperative xeloda chemotherapy and 25 cases without chemotherapy ( served as con-trols), and then the expression of TP/ PD-ECGF and MVD were analyzed.

方法：对32例术前应用希罗达化疗的和25例未做术前化疗的结直肠癌标本，进行TP/PD-ECGF、CD34免疫组织化学标记，检测其TP/PD-ECGF表达及微血管密度MVD。

Experimental Study on Changes of Expression of AFP mRNA in Human Hepatocellular Carcinoma Tissues after Oral Xeloda Therapy

希罗达对人肝癌组织AFP mRNA表达影响的实验研究

Therapy of Xeloda combined with oxaliplatin in advanced gastric cancer

希罗达联合草酸铂治疗晚期胃癌的临床观察

Objective: To evaluate the efficacy and tolerability of Xeloda as second line treatment for the patients with advanced breast cancer.

目的：评价希罗达对晚期乳腺癌患者二线化疗的有效率及耐受性。